MTL-CEBPA + pembrolizumab

A combination therapy consisting of **MTL-CEBPA**, a small activating RNA (saRNA) therapy that selectively upregulates the transcription factor CCAAT/enhancer-binding protein alpha (C/EBP-α), and **pembrolizumab**, a monoclonal antibody immune checkpoint inhibitor targeting PD-1. MTL-CEBPA is designed to relieve myeloid-driven immunosuppression in the tumor microenvironment (TME) by inducing differentiation of immature immunosuppressive myeloid cells, notably myeloid-derived suppressor cells (MDSCs), thus decreasing their immunosuppressive activity. Pembrolizumab blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), preventing T-cell inactivation. The combination aims to convert immunologically "cold" tumors, which are resistant to immunotherapy, into "hot" tumors with increased T-cell infiltration and enhanced anti-tumor response. Early clinical studies have focused on patients with advanced solid tumors showing resistance to immune checkpoint inhibitors.

Other names

anti-PD-1anti-PD1anti-PD 1anti-programmed death-1PD-1 inhibitorPD1 inhibitorPD 1 inhibitor